Clinical Trials Logo

Circulating Tumor DNA clinical trials

View clinical trials related to Circulating Tumor DNA.

Filter by:

NCT ID: NCT03688035 Not yet recruiting - Breast Cancer Clinical Trials

Potential of Circulating Tumor DNA to Assess the Tumor Response to Neoadjuvant Chemotherapy in Breast Cancer Patients

Start date: September 20, 2018
Phase:
Study type: Observational [Patient Registry]

Breast cancer is the most common malignant tumor in women worldwide,and there exist a large part of patients need to receive neoadjuvant chemotherapy(NAC) before the curative surgery.Circulating tumor DNA(ctDNA) is the circulating free DNA in the blood that originates from cancers,and it can be detected by modern technologies in plasma.In this prospective study,investigators aim to observe the correlation between tumor response to neoadjuvant chemotherapy and ctDNA.

NCT ID: NCT03615170 Recruiting - Rectal Neoplasms Clinical Trials

Application of Circulating Tumor DNA Test in the Diagnosis and Treatment of Patients With Advanced Rectal Cancer

Start date: July 19, 2017
Phase:
Study type: Observational [Patient Registry]

Application of circulating tumor DNA detection in diagnosis and treatment of locally advanced rectal cancer. First, to explore the feasibility of ctDNA as a detection index for rectal cancer. Second, evaluate the accuracy of ctDNA detection in rectal cancer. Third, to explore whether ctDNA can be used in the evaluation of preoperative concurrent chemoradiotherapy, so as to provide guidance for subsequent treatment. Fourth, to explore the guidance value for the decision of postoperative adjuvant therapy and the frequency of reexamination. Fifth, search for possible recurrence related mutations.

NCT ID: NCT03481101 Recruiting - Clinical trials for Non Small Cell Lung Cancer

WHENII - Early Response Evaluation With FDG-PET/CT and Liquid Biopsy in Patients With NSCLC

WHENII
Start date: February 28, 2018
Phase: N/A
Study type: Interventional

Response evaluation with FDG-PET and free circulating DNA in patients with inoperable lung cancer of non small cell type during first treatment with chemotherapy or immunotherapy.

NCT ID: NCT02620527 Completed - Cancer Clinical Trials

Concordance Between ctDNA Assay and FoundationOne

Start date: November 2014
Phase:
Study type: Observational

Foundation Medicine Inc. (FMI) is interested in studying the concordance of genomic alterations between primary and/or metastatic surgical biopsies, and circulating tumor DNA (ctDNA) within different solid tumor types and has been developing an assay in order to do so.